BLLN·Nasdaq·US
BillionToOne
BillionToOne develops and commercializes molecular diagnostics focused on non-invasive prenatal screening and liquid biopsy testing for oncology. Its products generate revenue through clinical testing services sold to healthcare providers and patients.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.